Browse SCYL2

Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, perinuclear region. Cytoplasmic vesicle, clathrin-coated vesicle. Golgi apparatus, trans-Golgi network membrane. Endosome membrane. Note=According to PubMed:15809293, plasma membrane-associated in clathrin-coated vesicles. According to PubMed:16914521, colocalizes to the trans-Golgi network (TGN) and to endosomal membranes with clathrin, transferrin and plasma membrane adapter AP1 and AP3 complexes.
Domain PF00069 Protein kinase domain
Function

Component of AP2-containing clathrin coated structures at the plasma membrane or of endocytic coated vesicles. According to PubMed:15809293, probable serine/threonine-protein kinase that phosphorylates, in vitro, the beta2-subunit of the plasma membrane adapter complex AP2 and other proteins in presence of poly-L-lysine. According to PubMed:16914521, has no detectable kinase activity in vitro. May regulate clathrin-dependent trafficking between the TGN and/or the endosomal system.

> Gene Ontology
 
Biological Process GO:0002090 regulation of receptor internalization
GO:0002092 positive regulation of receptor internalization
GO:0006898 receptor-mediated endocytosis
GO:0007034 vacuolar transport
GO:0007041 lysosomal transport
GO:0008333 endosome to lysosome transport
GO:0016055 Wnt signaling pathway
GO:0016197 endosomal transport
GO:0030100 regulation of endocytosis
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0031623 receptor internalization
GO:0043112 receptor metabolic process
GO:0045807 positive regulation of endocytosis
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048260 positive regulation of receptor-mediated endocytosis
GO:0060070 canonical Wnt signaling pathway
GO:0060627 regulation of vesicle-mediated transport
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0072583 clathrin-dependent endocytosis
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0198738 cell-cell signaling by wnt
GO:2000286 receptor internalization involved in canonical Wnt signaling pathway
GO:2000369 regulation of clathrin-dependent endocytosis
GO:2000370 positive regulation of clathrin-dependent endocytosis
Molecular Function -
Cellular Component GO:0010008 endosome membrane
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SCYL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SCYL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SCYL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0580.848
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2290.893
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.060.959
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1080.792
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4090.833
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2710.911
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0970.804
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2020.907
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0090.996
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2640.79
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8160.598
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0650.314
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SCYL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.8014.80.00448
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.8014.80.00826
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SCYL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SCYL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SCYL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SCYL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SCYL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SCYL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSCYL2
NameSCY1-like, kinase-like 2
Aliases KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ......
Chromosomal Location12q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SCYL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.